Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
In a turbulent market environment, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock has reached a 52-week low, dipping to $8.56. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, with a strong balance sheet showing more cash than debt. The biotechnology firm, which focuses on the development of transformative medicines, has faced significant headwinds over the past year, reflected in a stark 1-year change with a decline of -72.87%. Investors have shown concern as the company navigates through a challenging phase, marked by this new low point in its stock price trajectory. The 52-week low serves as a critical indicator for shareholders and potential investors, signaling a period of reassessment for the company’s market strategy and growth potential. With a current market capitalization of $230 million and analysts setting price targets between $44 and $140, InvestingPro analysis suggests the stock may be undervalued at current levels, though investors should note that five analysts have recently revised their earnings expectations downward.
In other recent news, Arcturus Therapeutics has been the focus of several analyst updates and company announcements. BTIG analyst Thomas Shrader raised the price target for Arcturus to $58, maintaining a Buy rating, following insights from AtriCure (NASDAQ:ATRC)’s Investor Day, which highlighted ambitious revenue targets for the coming years. Meanwhile, H.C. Wainwright analyst Ed Arce adjusted Arcturus’s price target to $60 from $63, while still recommending a Buy, citing the expected interim data from the Phase 2 study of ARCT-032 for cystic fibrosis by mid-2025. Canaccord Genuity also revised its price target for Arcturus to $68 from $74, maintaining a Buy rating, reflecting updated expectations for the Japanese COVID vaccine market.
Additionally, BTIG analysts maintained a $48 price target, expressing optimism about Arcturus’s ongoing mRNA vaccine research, particularly the potential of its self-amplifying mRNA vaccine for influenza. Leerink Partners cut their price target from $70 to $65 but kept an Outperform rating, influenced by Arcturus’s full-year 2024 earnings report and pipeline updates. Arcturus reported a gross profit of $28 million from Kostaive in Japan for the fourth quarter of 2024, with future milestones anticipated in the European Union and the United States. The company is also progressing in its rare disease portfolio, with Phase 2 data for cystic fibrosis and ornithine transcarbamylase deficiency expected by mid-2025. These developments indicate continued interest and confidence from analysts in Arcturus’s strategic direction and research endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.